title: Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
abstract: Eleven patients with advanced APL were treated with ATO (0.15 mg/Kg daily). Eight (73%) achieved molecular CR, but 5 relapsed, 1 died in molecular CR, 1 was lost to follow-up and 1 is still alive in CR after allogeneic transplantation. We suggest that ATO may be effective also in advanced APL, but given the short CR, it seems indicated only in patients eligible for transplant procedures.
authors.forename: Ida
authors.initials: I
authors.lastname: Carmosino
authors.forename: Roberto
authors.initials: R
authors.lastname: Latagliata
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Avvisati
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Erica
authors.initials: E
authors.lastname: Finolezzi
authors.forename: Francesco
authors.initials: F
authors.lastname: Lo Coco
authors.forename: Maria Concetta
authors.initials: MC
authors.lastname: Petti
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide